Related Experiment Videos
Sodium valproate in the treatment of the intractable childhood epileptic
Insights
Sodium valproate (valproate) effectively reduced seizure frequency in 60% of children with poorly controlled epilepsy. This anticonvulsant is a promising treatment option for intractable childhood seizure disorders.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
- Epileptology
Background:
- Children with seizure disorders often exhibit poor control despite multiple anticonvulsant therapies.
- Intractable epilepsy in childhood presents significant management challenges.
Purpose of the Study:
- To evaluate the efficacy and tolerability of sodium valproate (valproate) in children with poorly controlled seizure disorders.
- To assess the response to valproate across various seizure classifications.
Main Methods:
- Sixty-five children with intractable seizures were treated with sodium valproate.
- Oral administration, pharmacokinetic parameters (peak plasma levels, half-life), and side effects were monitored.
- Seizure frequency reduction was the primary efficacy measure.
Main Results:
- Sodium valproate demonstrated rapid oral absorption with a mean plasma half-life of 12.8 hours.
- Sixty percent of patients experienced over a 50% reduction in seizure frequency.
- Generalized absence seizures showed the best response, though all seizure types showed some improvement.
- Reported side effects were minimal, with notable drug interactions with phenobarbital, diphenylhydantoin, and clonazepam.
Conclusions:
- Sodium valproate is a well-tolerated and effective treatment for a significant proportion of children with intractable seizure disorders.
- A trial of sodium valproate is recommended for childhood epilepsy regardless of seizure classification due to its broad efficacy.
Abstract:
Sixty-five children with seizure disorders, who had been treated with multiple anticonvulsants but were poorly controlled, were selected from the Montreal Children's Hospital Convulsive Disorder Clinic and Neurology Service and were treated with sodium valproate (valproate). All types of seizure disorders were included in the group. Rapid oral absorption of the drug lead to peak plasma levels in one to three hours (later peaks occurring if administered after meals). A mean plasma half-life of 12.8 hours was calculated. Correlation between oral dose and plasma levels was poor. The side effects which occurred in this study were trivial. Drug interactions occurred with phenobarbital, diphenylhydantoin and clonazepam. Sixty percent of patients had a greater than 50% reduction in seizure frequency with sodium valproate, but the best response was in generalized absence seizures. Since all types of seizures responded to some degree, a trial of sodium valproate is warranted in intractable seizure disorders of childhood regardless of classification.